Resources for Clinicians
Resources for Healthcare Professionals
Cabaletta Bio Presents Promising Early Data on CAR-T Therapy for Myositis
We expected to hear promising news about the potential for CAR-T therapy to treat myositis at the Global Conference on Myositis (GCOM).
What we heard was more than promising—it was astounding.
What if I told you that there was a therapy that would “reset” the immune system—virtually eliminating the autoimmune response in myositis that causes inflammation, pain, muscle weakness, and other JM conditions of which we are all too familiar.
What We Know About Calcinosis & How to Treat It
Medically Reviewed by Angela Chun, MD on February 9, 2026 and Belina Yi, DO on February 25, 2026. Cure JM shares medical resources to support informed conversations
Home IVIG: A Family Perspective
Medically Reviewed by Dawn Wahezi, MD, MS on January 26, 2026. Cure JM shares family experiences to support informed conversations between families and their care teams. Intravenous
February 2026 Town Hall – Through Their Eyes: A Q&A Panel of Young Adults Living with JM
Our February Town Hall featured a conversation designed for parents, grandparents, and caregivers navigating life with Juvenile Myositis. A small panel of young adults in
Shared DNA Clues Point to Faster Treatments for Juvenile Myositis
In a study funded by the Cure JM Foundation and spearheaded by Dr. Younghun Han of the Baylor College of Medicine, scientists compared the DNA of more than three thousand people living with myositis to nearly twelve thousand healthy volunteers and found something striking. The major forms of myositis share much of the same genetic wiring.
RESET-Myositis Trial: CAR-T Cell Therapy (CABA-201)
Contact Info: A phase 1/ 2 clinical trial, investigating a treatment that uses your own T cells to treat myositis Who Can Participate: A study
Understanding Skin Symptoms in Juvenile Dermatomyositis: What Parents Can Learn from Recent Research
Based on a presentation by Grace A. Osborne, MD, PhD, Pediatric Dermatologist, University of Michigan at the January 2026 Cure JM Virtual Summit on JIIM
Descartes‑08: A New CAR‑T Trial for Juvenile Myositis and What Parents Should Know
Based on a presentation by Miloš Miljković, MD, PhD, Chief Medical Officer, Cartesian Therapeutics at the January 2026 Cure JM Virtual Summit on JIIM Research
Cure JM Virtual Summit on Juvenile Idiopathic Inflammatory Myopathies – January 2026
January 15, 2026 In January, the Cure JM Clinical Care Network was pleased to invite juvenile dermatomyositis healthcare professionals to join us virtually for the
December Town Hall – Live from Giving Tuesday
This Giving Tuesday, families and supporters joined us for an exciting update on the breakthroughs accelerating JM research and care. Executive Director Jim Minow walked
Join Cure JM
Sign up and you will receive the quarterly Cure JM newsletter for clinicians and physicians.
